Research Article
Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Table 2
Grading the evidence with GRADEpro guideline development tool.
| | Certainty assessment | No. of patients | Effect | Certainty | Importance | | No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Baricitinib | Control | Relative (95% CI) | Absolute (95% CI) |
| | Mortality (4 RCTs) |
| | 4 | Randomised trials | Seriousa | Not serious | Not serious | Not serious | None | 619/5478 (11.3%) | 712/5337 (13.3%) | RR 0.74 (0.58 to 0.94) | 35 fewer per 1,000 (from 56 fewer to 8 fewer) | ⊕⊕⊕ ⃝
Moderate | Critical | | Disease progression (3 RCTs) |
| | 3 | Randomised trials | Seriousa | Not serious | Not serious | Not serious | None | 454/5239 (8.7%) | 528/5113 (10.3%) | RR 0.84 (0.75 to 0.95) | 17 fewer per 1,000 (from 26 fewer to 5 fewer) | ⊕⊕⊕ ⃝
Moderate | Critical |
|
|
CI: confidence interval; RR: risk ratio. aOpen-label study [ 12]. |
